Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Sinus surgery is more effective than antibiotics at treating chronic rhinosinusitis, according to a major clinical trial led by UCL, coordinated by the Oxford Clinical Trials Research Unit (OCTRU) and Surgical Intervention Trials Unit (SITU) at NDORMS, in collaboration with researchers across the UK.

Woman having surgery for sinus disease © Shutterstock

Chronic rhinosinusitis (CRS), or sinusitis, is a long-term condition affecting one in 10 UK adults. Symptoms include a blocked and runny nose, loss of smell, facial pain, tiredness and worsening of breathing problems, such as asthma. It’s often similar to the symptoms of a bad cold, but it can last for months or even years.

The team carried out a randomised controlled patient trial comparing sinus surgery with long-term use of antibiotics, and a placebo drug.

More than 500 patients took part from around the UK, and all of them used nasal steroids and saline rinses as part of their usual care – both of which have been shown to help the condition.

The researchers found that surgery was most effective at relieving sinusitis symptoms, and trial participants were still feeling better six months later, according to the findings published in The Lancet. Of those who underwent surgery, 87% said their quality of life had improved six months on.

A three-month course of low dose antibiotics was not found to be helpful as there was no significant difference in outcomes between those on antibiotics and those in the placebo arm of the trial.

The study is part of the MACRO programme, involving a collaborative group of researchers from UCL (the trial’s sponsor), the University of Oxford, the University of East Anglia (UEA), Guy’s and St Thomas’ NHS Foundation Trust, the University of Southampton, UCLH, and Imperial College London. The programme is funded by the National Institute for Health and Care Research.

Professor Jonathan Cook, Interim Co-Director of OCTRU and chief methodologist for the study said: ‘Chronic rhinosinusitis can have a major effect on quality of life but there has been some uncertainty about the benefit of surgery to patients despite widespread use. Additionally, the potential benefit of clarithromycin, an antibiotic used to treat various infections, was unclear. This has contributed to varying access to different treatment options for patients across the UK in recent years. It’s has been great to be involved from the beginning to shape the design of MACRO study to ensure it addresses these two important areas of uncertainty. OCTRU was set-up to deliver important studies like this, which are designed and conducted in a reliable way, and in order to help patients and doctors make informed decisions.’ 

For the trial, all participants received nasal steroids and saline rinses as standard care, alongside their randomly allocated treatment option of either sinus surgery, antibiotics or placebo tablets. They were followed up after three and six months, where researchers examined their nose and sinuses, took airflow readings and conducted smell tests to gauge the success of each treatment in terms of improvement of symptoms, quality of life and possible side effects.

Professor David Beard, Director of SITU and one of the co-applicants said: ‘The findings of our study could be a game-changer for patients worldwide. The efficient trial design for MACRO (answering two questions at once) is exactly the sort of evaluation we should be doing to discover the efficacy of common surgery and pharmaceutical interventions. It has been a longish journey but the commitment of all our investigators, clinicians, research nurses, and of course our patient participants across 20 UK sites, has delivered a wonderful landmark study.’

Jim Boardman, MACRO patient representative, said: 'I’ve lived under a cloud for years with CRS, as have many others I’ve met with the same condition. There’s a persistent headache and blocked nose along with the loss of sense of smell, which removes a whole dimension of everyday experience and enjoyment. A clear path to successful treatment will be welcomed by all CRS sufferers.'

The researchers are now continuing their research to assess the cost-effectiveness of sinus surgery, while also continuing to follow up trial participants over longer periods of time to see how long the benefits last.

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.